NASDAQ: PRTC - PureTech Health plc

Rentabilidade por seis meses: -14.52%
Rendimento de dividendos: 0.00%
Setor: Healthcare

Cronograma de promoção PureTech Health plc

Agenda avançada Gráfico simples
Financial Markets by TradingView

Sobre a empresa PureTech Health plc

PureTech Health plc, a clinical stage biotherapeutics company, engages in the discovery, development, and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, currently under Phase 3 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, to inhibit the activity of galectin-9 for treating solid tumors and hematological malignancies.

mais detalhes
It is also developing LYT-300, an oral allopregnanolone, currently completed Phase 1 stage, to treat depression, anxiety, and related indications; and LYT-310, an oral cannabidiol, currently under preclinical stage, to treat epilepsies and other neurological indications. In addition, the company is developing LYT-503/IMB-150, a non-opioid inflammation targeted disease immunomodulation for the potential treatment of interstitial cystitis, or bladder pain syndrome; and Glyph technology platform, a lymphatic-targeting chemistry platform, which leverages the body's natural lipid absorption and transports the process to orally administer drugs via the lymphatic system. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Adicionar à lista de comparação
Adicionar à lista de observação
Adicionar ao portfólio
Adicionar aviso de preço

IPO date 2020-11-16
ISIN US7462371060
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.puretechhealth.com
Цена ао 16.75
Alteração de preço por dia: -0.4407% (17.7)
Alteração de preço por semana: +5.47% (16.7088)
Alteração de preço por mês: -6.71% (18.89)
Alteração de preço em 3 meses: -9.68% (19.51)
Mudança de preço em seis meses: -14.52% (20.615)
Mudança de preço por ano: -38.17% (28.5)
Mudança de preço em 3 anos: -38.77% (28.78)
Mudança de preço desde o início do ano: -9.68% (19.51)
Todos os parâmetros

Subestimação

Nome Significado Nota
P/S 211.58 1
P/BV 1.24 9
P/E 0 0
EV/EBITDA -3.8 0
Total: 3.63

Eficiência

Nome Significado Nota
ROA, % -9.47 0
ROE, % -14.16 0
Total: 0

Dividendos

Nome Significado Nota
Div yield, % 0 0
DSI 0 0
Total: 0.0657

Obrigação

Nome Significado Nota
Debt/EBITDA -0.1806 10
Total: 9.6

Impulso de crescimento

Nome Significado Nota
Rentabilidade Revenue, % -61.72 0
Rentabilidade Ebitda, % -87.75 0
Rentabilidade EPS, % -101.65 0
Total: 0
Mais detalhes

Instituições Volume Compartilhar, %
Pentwater Capital Management LP 10244 0.04
Tower Research Capital LLC (TRC) 43 0
UBS Group AG 20 0

ETFCompartilhar, %Rentabilidade para o ano, %Dividendos, %
Amplify BlueStar Israel Technology ETF 0.30643 20.42 0.47569
Invesco Global Listed Private Equity ETF 0.29338 29.43 3.4983
Dimensional International Small Cap ETF 0.02653 5.69 3.34747
SPDR S&P International Small Cap ETF 0.0233 8.94 3.10348
Schwab International Small-Cap Equity ETF 0.0133 10.07 3.20638
SPDR Portfolio Europe ETF 0.00347 8.94 3.66537
Dimensional International Core Equity 2 ETF 0.00136 6.52 3.69996
Avantis International Equity ETF 0.00099 6.46 3.80856
Dimensional International Core Equity Market ETF 0.00032 13.09 3.48343
Vanguard FTSE All-World ex-US Small-Cap ETF 0 9.39 3.09932
Vanguard ESG International Stock ETF 0 6.39 3.07501
0.0611.393.13



Supervisor Cargo Pagamento Ano de nascimento
Ms. Daphne Zohar Founder, Senior Advisor & Board Observer 3.99M 1971 (54 ano)
Dr. Bharatt M. Chowrira J.D., Ph.D. CEO & Executive Director 2.19M 1965 (60 anos)
Dr. David R. Elmaleh Ph.D. Co-Founder & Senior Advisor N/A 1948 (77 anos)
Ms. Allison Mead Talbot Head of Communications & Investor Relations N/A
Mr. Spencer Ball Senior Vice President of Human Resources N/A
Dr. Eric Elenko Ph.D. Co-Founder & President N/A 1973 (52 ano)
Mr. Eric Green M.B.A. Chief Operating Officer N/A
Mr. Charles Sherwood III, J.D., Ph.D. General Counsel & Company Secretary N/A
Dr. Robert S. Langer Jr., Ph.D., ScD Co-Founder & Non-Executive Director 1949 (76 anos)
Mr. Michael Inbar CPA, M.B.A. Senior Vice President of Finance

Endereço: United States, Boston. MA, 6 Tide Street - abrir no Google Maps, abrir mapas Yandex
Site: https://www.puretechhealth.com